Chemical Synthesis and Immunological Properties of Oligosaccharides Derived from the Vegetative Cell Wall of Bacillus anthracis

Abstract

Bacillus anthracis vaccine candidate: Sera of rabbits exposed to live and irradiated-killed spores of B. anthracis Sterne 34F2 or immunized with B. anthracis polysaccharide conjugated to KLH elicited antibodies that recognize isolated polysaccharide and two synthetic trisaccharides providing a proof-of-concept step in the development of vegetative and spore-specific reagents for detection and targeting of non-protein structures of B. anthracis.

Glycan surface antigens fromBacillus anthracisas vaccine targets: current status and future perspectives

“…The 10-30-fold stronger binding for the isolated SCWP in comparison to the synthetic hexasaccharide was explained as result of the polyvalent binding mode of the polysaccharide that comprised an average of 10 repeating units [52]. Antibodies against synthetic fragments of SCWP were induced in mice following vaccination with Keyhole limpet hemocyanin conjugates [54]. Anti-irradiated B. anthracis Sterne 34F2 spores antisera were shown to recognize the glycan structures, providing the first demonstration of the immunogenicity of SCWP-based conjugates.…”

Synthetische Oligosaccharide belegen die immunologische Bedeutung der Pyruvatmodifikation im Kapselpolysaccharid von Serotyp 4 Streptococcus pneumoniae

“…Chemie nukleophil ersetzt werden. [12] Die Kopplungskonstanten im vollständig geschützten Te trasaccharid vor (J = 7.2 Hz) und nach Inversion (J = 1.2 Hz) belegen eindeutig die Bildung der gewünschten b-mannosidischen Bindung.…”

Immunologic mapping of glycomes: implications for cancer diagnosis and therapy

“…Glycans and glycolipids are recognized as targets for immunodiagnosis and immunotherapy in multiple diseases; examples include 1) Tn antigens, a family of under-glycosylated mucin proteins expressed in more than 80% of cancer patients, which are being used both as cancer markers (CA125, CA15.3 and CA2.29) and vaccine candidates (67); 2) GM2, GD2, GD3, and other gangliosides, which are being evaluated as vaccine candidates in melanoma and neuroblastoma clinics (68, 69); and 3) GbH, which is being evaluated as a biomarker and vaccine candidate in breast cancer clinics (70). Important clinical applications have already been developed in several areas: 1) cancer vaccines, such as Tn glycans and GM2; 2) tumoricidal antibodies or toxins, such as anti-GD2 and anti-MUC1; and 3) diagnostic reagents for pathogens, such as the monoclonal antibodies for anthrax spore glycans (71, 72) and Chaga’s disease (73). …”